PCN91 COST-EFFECTIVENESS OF IMMUNOTHERAPY-BASED DRUG REGIMENS FOR THE INITIAL TREATMENT OF PATIENTS WITH METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Nov 1, 2019, 00:00 AM
10.1016/j.jval.2019.09.288
https://www.valueinhealthjournal.com/article/S1098-3015(19)32666-X/fulltext
Section Title :
Section Order :
10231
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32666-X&doi=10.1016/j.jval.2019.09.288